by Alison Bass | Apr 13, 2016 | antidepressants, antipsychotic drugs, clinical trials, conflicts of interest, drug marketing, FDA, pharmaceutical industry, prostitution, sex work
After my first nonfiction book, Side Effects: A Prosecutor, a Whistleblower and a Bestselling Antidepressant on Trial, was published, a number of readers told me that the book would make a great movie. (It’s written as a narrative and tells the true story of two...
by Alison Bass | Jun 10, 2013 | antidepressants, antipsychotic drugs, conflicts of interest, drug marketing, FDA, pharmaceutical industry, prescription drug abuse, scientific misconduct
I reviewed two books now circulating about the DSM and the current controversy over the DSM-5 for The American Scholar — see review here. The two books are The Book of Woe: The DSM and the Unmaking of Psychiatry by Gary Greenberg, and Saving Normal: An Insider’s...
by Alison Bass | Sep 10, 2012 | antidepressants, antipsychotic drugs, drug marketing, health care costs, patient care, pharmaceutical industry, prescription drug overdoes, public health
Did you know that West Virginia has the second highest rate of deaths from prescription drug overdoses in the country? I didn’t, until I moved to the Mountain State to live and work and became curious as to what was behind this tragic statistic. According to a...
by Alison Bass | Jul 3, 2012 | antidepressants, antipsychotic drugs, clinical trials, drug marketing, patient care, pharmaceutical industry, scientific journal retractions, scientific misconduct, suicide rates, whistleblowing
I was glad to see that the New York Times’ reporters covering GlaxoSmithKline’s $3 billion settlement tipped their hat to former New York Attorney General Eliot Spitzer. After all, it was his crew and specifically a pioneering attorney by the name of Rose...
by Alison Bass | Apr 12, 2012 | antidepressants, antipsychotic drugs, clinical trials, drug marketing, FDA, health care costs, patient care, pharmaceutical industry, scientific misconduct
I’ve been reading Dr. David Healy’s new book, Pharmageddon, and while some of it may seem like old news, I was struck by his fresh analysis of how the pharmaceutical industry has turned the original purpose of clinical trials inside out. As Healy, a noted...
by Alison Bass | Jan 18, 2012 | antipsychotic drugs, conflicts of interest, drug marketing, expert testimony, media coverage, pharmaceutical industry, whistleblowing
Allen Jones, the whistleblower in an ongoing landmark trial against the pharmaceutical giant Johnson & Johnson, was very much on my mind this past weekend. I was participating in a workshop to develop curriculum to teach college students about the importance of...